(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 January 2007 (25.01.2007)

PCT

(10) International Publication Number
WO 2007/011941 A3

(51) International Patent Classification:
C07K 16/28 (2006.01) *G01N 33/68* (2006.01)
A61P 37/00 (2006.01) *G01N 33/577* (2006.01)
A61P 11/06 (2006.01) *C12N 15/13* (2006.01)
A61K 39/395 (2006.01) *C12N 5/10* (2006.01)

(21) International Application Number:
PCT/US2006/027862

(22) International Filing Date: 18 July 2006 (18.07.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/700,265 18 July 2005 (18.07.2005) US

(71) Applicants *(for all designated States except US)*: **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US). **MEDAREX INC.** [US/US]; 707 State Road, Princeton, NJ 08540 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **SIU, Gerald** [US/US]; 1730 California Avenue, #5, Santa Monica, CA 90403 (US). **SHEN, Wenyan** [CA/US]; 3456 Bryant Street, Palo Alto, CA 94306 (US). **YOSHINAGA, Steven, Kiyoshi** [US/US]; 1896 Calle Salto, Thousand Oaks, CA 91360 (US). **HUANG, Haichun** [US/US]; 2425 Sueno Way, Fremont, CA 94539 (US).

(74) Agent: **DERRY, Jason, J.**; MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP, 300 South Wacker Drive, Suite 3100, Chicago, IL 60606 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*

(88) Date of publication of the international search report:
3 May 2007

(48) Date of publication of this corrected version:
21 February 2008

(15) Information about Correction:
see Notice of 21 February 2008

(54) Title: HUMAN ANTI-B7RP1 NEUTRALIZING ANTIBODIES

(57) Abstract: This invention provides antibodies that interact with or bind to human B7 related protein-1 (B7RP1) and antibodies that bind to and neutralize the function of B7RP1 thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing B7RP1 function, and particularly for treating immune disorders (e.g., inappropriate immune response) by administering a pharmaceutically effective amount of anti-B7RPl antibodies. Methods of detecting the amount of B7RP1 in a sample using anti-B7RPl antibodies are also provided.

WO 2007/011941 A3